Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib

Angela Listi', Francesco Passiglia, Marco Giallombardo, Edgardo Santos, Luis Corrales, Francesco Passiglia, Christian Caglevic, Marco Giallombardo, Amanda Nogueira, Christian Rolfo, Luis Raez, Christian Diego Rolfo

Risultato della ricerca: Article

4 Citazioni (Scopus)

Abstract

Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targetable oncogenic drivers are docetaxel, gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC). Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors (vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor). Several preclinical and clinical studies have proven the usefulness of nintedanib as an anticancer agent for NSCLC. The most important study was the phase III LUME-Lung 1 trial, which investigated the combination of nintedanib with docetaxel for second-line treatment in advanced NSCLC patients. The significant improvement in overall survival and the manageable safety profile led to the approval of this new treatment in Europe. This review focuses on the preclinical and clinical studies with nintedanib in NSCLC.
Lingua originaleEnglish
Numero di pagine0
RivistaFrontiers in Medicine
Volume4
Stato di pubblicazionePublished - 2017

Fingerprint

Non-Small Cell Lung Carcinoma
docetaxel
gemcitabine
Pemetrexed
Therapeutics
Lung
Vascular Endothelial Growth Factor Receptor
Angiogenesis Inhibitors
Fibroblast Growth Factors
Platelet-Derived Growth Factor
Oncogenes
Antineoplastic Agents
Protein-Tyrosine Kinases
Disease Progression
Cause of Death
nintedanib
Carcinoma
Safety
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cita questo

Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. / Listi', Angela; Passiglia, Francesco; Giallombardo, Marco; Santos, Edgardo; Corrales, Luis; Passiglia, Francesco; Caglevic, Christian; Giallombardo, Marco; Nogueira, Amanda; Rolfo, Christian; Raez, Luis; Rolfo, Christian Diego.

In: Frontiers in Medicine, Vol. 4, 2017.

Risultato della ricerca: Article

Listi', A, Passiglia, F, Giallombardo, M, Santos, E, Corrales, L, Passiglia, F, Caglevic, C, Giallombardo, M, Nogueira, A, Rolfo, C, Raez, L & Rolfo, CD 2017, 'Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib', Frontiers in Medicine, vol. 4.
Listi', Angela ; Passiglia, Francesco ; Giallombardo, Marco ; Santos, Edgardo ; Corrales, Luis ; Passiglia, Francesco ; Caglevic, Christian ; Giallombardo, Marco ; Nogueira, Amanda ; Rolfo, Christian ; Raez, Luis ; Rolfo, Christian Diego. / Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. In: Frontiers in Medicine. 2017 ; Vol. 4.
@article{31a5c1065a0b49fc81ca986f267ded3a,
title = "Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib",
abstract = "Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targetable oncogenic drivers are docetaxel, gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC). Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors (vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor). Several preclinical and clinical studies have proven the usefulness of nintedanib as an anticancer agent for NSCLC. The most important study was the phase III LUME-Lung 1 trial, which investigated the combination of nintedanib with docetaxel for second-line treatment in advanced NSCLC patients. The significant improvement in overall survival and the manageable safety profile led to the approval of this new treatment in Europe. This review focuses on the preclinical and clinical studies with nintedanib in NSCLC.",
author = "Angela Listi' and Francesco Passiglia and Marco Giallombardo and Edgardo Santos and Luis Corrales and Francesco Passiglia and Christian Caglevic and Marco Giallombardo and Amanda Nogueira and Christian Rolfo and Luis Raez and Rolfo, {Christian Diego}",
year = "2017",
language = "English",
volume = "4",
journal = "Frontiers in Medicine",
issn = "2296-858X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib

AU - Listi', Angela

AU - Passiglia, Francesco

AU - Giallombardo, Marco

AU - Santos, Edgardo

AU - Corrales, Luis

AU - Passiglia, Francesco

AU - Caglevic, Christian

AU - Giallombardo, Marco

AU - Nogueira, Amanda

AU - Rolfo, Christian

AU - Raez, Luis

AU - Rolfo, Christian Diego

PY - 2017

Y1 - 2017

N2 - Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targetable oncogenic drivers are docetaxel, gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC). Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors (vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor). Several preclinical and clinical studies have proven the usefulness of nintedanib as an anticancer agent for NSCLC. The most important study was the phase III LUME-Lung 1 trial, which investigated the combination of nintedanib with docetaxel for second-line treatment in advanced NSCLC patients. The significant improvement in overall survival and the manageable safety profile led to the approval of this new treatment in Europe. This review focuses on the preclinical and clinical studies with nintedanib in NSCLC.

AB - Lung carcinoma is the leading cause of death by cancer in the world. Nowadays, most patients will experience disease progression during or after first-line chemotherapy demonstrating the need for new, effective second-line treatments. The only approved second-line therapies for patients without targetable oncogenic drivers are docetaxel, gemcitabine, pemetrexed, and erlotinib and for patients with target-specific oncogenes afatinib, osimertinib, crizotinib, alectinib, and ceritinib. In recent years, evidence on the role of antiangiogenic agents have been established as important and effective therapeutic targets in non-small cell lung cancer (NSCLC). Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors (vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor). Several preclinical and clinical studies have proven the usefulness of nintedanib as an anticancer agent for NSCLC. The most important study was the phase III LUME-Lung 1 trial, which investigated the combination of nintedanib with docetaxel for second-line treatment in advanced NSCLC patients. The significant improvement in overall survival and the manageable safety profile led to the approval of this new treatment in Europe. This review focuses on the preclinical and clinical studies with nintedanib in NSCLC.

UR - http://hdl.handle.net/10447/244862

M3 - Article

VL - 4

JO - Frontiers in Medicine

JF - Frontiers in Medicine

SN - 2296-858X

ER -